Short-Term Intensive Insulin Therapy Induction of Long-Term Glycemic Control
Recruitment status was Recruiting
We designed this prospective, randomized control study to compare the benefits between the insulin therapy and OADs after correction of the glucose toxicity with a short period of intensive insulin therapy.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Short-Term Intensive Insulin Therapy Induction of Long-Term Glycemic Control Is Associated With Improvement of ß-Cell Function in Newly Diagnosed Type 2 Diabetic Patients|
- Short-term intensive insulin therapy can decrease the insulin resistance and improve the Beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia. [ Time Frame: 6 months ]
- Improve long term glycemic control [ Time Frame: 5 years ]
|Study Start Date:||October 2005|
|Estimated Study Completion Date:||December 2011|
Insulin therapy was initiated at a 75% total daily dose in the last day hospitalization with insulatard. Two third of daily dose was admmistrated before breakfask and the other was admmistrated at bedtime. Insulin doses were titrated every 3 days to achieve target FPG and pre-supper blood glucose values between 90 and 130 mg/dl. Bedtime insulin doses were titrated based on FPG values and the pre breakfast dose was titrated base on presupper blood glucose.
Other Name: Insulatard, Actrapid, Lantus, monotard
Active Comparator: OAD
Subject in other OAD group was visited every two weeks in the two months and the every four weeks. The subjects will start with Gliclazide-MR 30mg before breakfast, The dosage was titrated based on the fasting blood glucose on the visiting day with the same target. Decreased by 30mg if blood glucose was <70mg /dl, decreased by 15 mg if blood glucose was 70-90mg/dl, no change if blood glucose was 90-130mg/dl, increased by 15 mg if blood glucose was 131-160 mg/dl, increased by 30 mg if blood glucose >160mg/dl. When the Gliclazide-MR dose each to the maximum dose of 60 mg twice daily, Metformin was added. The titration of Metformin was use 250mg for an adjust dosage with the same target.
Gliclazide-MR, Metformin, Glimepiride
Other Name: Diamicron-MR, Glucophage, Amaryl
OBJECTIVE—Type 2 diabetes is associated with defects in insulin secretion and insulin action. Hyperglycemia may aggravate these defects, a feature known as glucose toxicity. Previous studies have shown that acute correction of hyperglycemia in subjects with long-standing type 2 diabetes gives only short-term improvement in glycemic control after discontinuation of insulin. The current study attempts to identify any characteristics of patients with newly diagnosed type 2 diabetes (fasting glucose >300mg/dL) who would have a long-term benefit, in terms of glycemic control, from a brief course of insulin therapy.
RESEARCH DESIGN AND METHODS—Newly diagnosed type 2 diabetic patients with severe hyperglycemia (fasting blood glucose >300 mg/dL or random blood glucose >400 mg/dL) will be hospitalized and treated with intensive insulin injection for 10 to 14 days. Oral glucose tolerance will be performed after one week of intensive insulin treatment. After discharge, patients will be randomized to receive insulin injection or oral anti-diabetic drug for further management. Patients will be followed in our clinics and adjust their medication according to their blood glucose levels. Oral glucose tolerance test will be repeated 6 months later, whereas the insulin sensitivity and -cell function will be evaluated again.
EXPECTED RESULTS—We will respect that short-term intensive insulin therapy can induce lone-term glycemic control in newly diagnosed type 2 diabetes with severe hyperglycemia.
|Contact: Harn-Shen Chen, MD, PhDemail@example.com|
|Contact: Cho-yu Chan, MDfirstname.lastname@example.org|
|Division of Endocrinology and Metabolism, Department of Medicine||Recruiting|
|Taipei, Taiwan, 112|
|Contact: Harn-Shen Chen, MD, PhD 886-2-28757515 email@example.com|
|Contact: Cho-yu Chan, MD 886-2-28757434 firstname.lastname@example.org|
|Principal Investigator: Han-Shen Chen, MD, PhD|
|Principal Investigator:||Harn-Shen Chen, MD, PhD||Division of endocrinology and metabolism, Department of medicien, Taipei Veterans General Hospital|